Financial Snapshot

Revenue
$1.098B
TTM
Gross Margin
55.0%
TTM
Net Earnings
$39.89M
TTM
Current Assets
Q2 2024
Current Liabilities
Q2 2024
Current Ratio
293.38%
Q2 2024
Total Assets
Q2 2024
Total Liabilities
Q2 2024
Book Value
$422.8M
Q2 2024
Cash
Q2 2024
P/E
119.3
Sep 13, 2024 EST
Free Cash Flow
$32.28M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018
Revenue $1.049B $1.004B $931.5M $818.2M $778.3M $746.1M
YoY Change 4.54% 7.75% 13.85% 5.12% 4.32%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018
Revenue $1.049B $1.004B $931.5M $818.2M $778.3M $746.1M
Cost Of Revenue $472.1M $446.7M $412.8M $374.6M $382.9M $388.9M
Gross Profit $577.2M $557.0M $518.7M $443.6M $395.4M $357.3M
Gross Profit Margin 55.0% 55.5% 55.68% 54.22% 50.81% 47.89%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018
Selling, General & Admin $236.7M $245.7M $198.2M $178.5M $147.5M $133.4M
YoY Change -3.68% 24.0% 11.0% 21.05% 10.55%
% of Gross Profit 41.01% 44.11% 38.2% 40.25% 37.3% 37.34%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $76.60M $64.30M $64.20M $63.30M $66.70M $146.8M
YoY Change 19.13% 0.16% 1.42% -5.1% -54.56%
% of Gross Profit 13.27% 11.54% 12.38% 14.27% 16.87% 41.09%
Operating Expenses $300.5M $308.7M $261.9M $237.6M $211.8M $191.3M
YoY Change -2.65% 17.83% 10.27% 12.14% 10.73%
Operating Profit $276.7M $248.4M $256.7M $206.0M $183.6M $166.0M
YoY Change 11.41% -3.27% 24.62% 12.21% 10.6%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018
Interest Expense -$142.9M -$80.14M -$74.19M -$215.3M -$157.7M -$155.4M
YoY Change 78.28% 8.02% -65.53% 36.47% 1.5%
% of Operating Profit -51.64% -32.27% -28.9% -104.49% -85.91% -93.61%
Other Income/Expense, Net $7.372M $6.441M $15.20M $9.413M $7.246M $2.900M
YoY Change 14.45% -57.63% 61.49% 29.91% 149.86%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018
Pretax Income $106.0M -$243.1M $175.7M -$38.86M -$916.0K $24.20M
YoY Change -143.61% -238.35% -552.18% 4142.36% -103.79%
Income Tax $54.65M -$9.541M $58.60M -$1.369M $19.51M $30.10M
% Of Pretax Income 51.54% 33.35% 124.38%
Net Earnings $51.38M -$233.6M $116.9M -$38.62M -$20.85M -$5.900M
YoY Change -122.0% -299.83% -402.67% 85.21% 253.39%
Net Earnings / Revenue 4.9% -23.27% 12.55% -4.72% -2.68% -0.79%
Basic Earnings Per Share $0.18 -$0.83 $0.41 -$0.16 -$0.09
Diluted Earnings Per Share $0.18 -$0.83 $0.41 -$0.16 -$0.09 -$21.27K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018
Cash & Short-Term Investments $296.4M $395.2M $106.9M $102.4M $62.90M $96.30M
YoY Change -25.0% 269.65% 4.41% 62.8% -34.68%
Cash & Equivalents $296.4M $395.2M $106.9M $102.4M $62.90M $96.30M
Short-Term Investments
Other Short-Term Assets $36.29M $56.93M $53.85M $62.90M $51.70M $58.70M
YoY Change -36.26% 5.72% -14.38% 21.66% -11.93%
Inventory $48.32M $37.15M $54.29M $34.10M $37.40M $37.60M
Prepaid Expenses
Receivables $165.5M $138.3M $123.7M $91.70M $88.60M $100.0M
Other Receivables $10.75M $17.46M $7.155M $23.90M $11.70M $20.30M
Total Short-Term Assets $557.2M $645.0M $346.0M $315.0M $252.4M $312.9M
YoY Change -13.61% 86.44% 9.83% 24.8% -19.34%
Property, Plant & Equipment $971.0M $801.0M $690.7M $655.8M $582.0M $586.4M
YoY Change 21.22% 15.96% 5.33% 12.68% -0.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $9.405M $13.50M
YoY Change -100.0% -30.33%
Other Assets $81.62M $85.96M $32.39M $17.70M $14.50M $19.90M
YoY Change -5.05% 165.41% 82.98% 22.07% -27.14%
Total Long-Term Assets $2.573B $2.473B $2.444B $2.446B $2.328B $2.396B
YoY Change 4.06% 1.19% -0.11% 5.07% -2.81%
Total Assets $3.130B $3.118B $2.790B $2.761B $2.581B $2.709B
YoY Change
Accounts Payable $71.04M $74.14M $72.87M $52.40M $42.00M $46.40M
YoY Change -4.18% 1.74% 39.06% 24.76% -9.48%
Accrued Expenses $124.5M $486.3M $64.82M $66.20M $54.90M $71.20M
YoY Change -74.4% 650.26% -2.09% 20.58% -22.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $13.57M $198.8M $1.160M $1.200M $17.60M $16.70M
YoY Change -93.18% 17041.47% -3.33% -93.18% 5.39%
Total Short-Term Liabilities $230.7M $791.6M $161.2M $140.6M $124.0M $143.4M
YoY Change -70.86% 391.17% 14.62% 13.39% -13.53%
Long-Term Debt $2.287B $1.804B $1.784B $1.860B $2.831B $2.221B
YoY Change 26.79% 1.1% -4.05% -34.3% 27.45%
Other Long-Term Liabilities $104.1M $103.8M $123.3M $170.9M $116.2M $113.5M
YoY Change 0.29% -15.83% -27.83% 47.07% 2.38%
Total Long-Term Liabilities $2.392B $1.908B $1.908B $2.031B $2.947B $2.335B
YoY Change 25.35% 0.01% -6.05% -31.1% 26.23%
Total Liabilities $2.687B $2.767B $2.203B $2.309B $3.223B $2.664B
YoY Change -2.92% 25.6% -4.57% -28.36% 20.98%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018
Basic Shares Outstanding 281.0M shares 280.1M shares 279.2M shares 237.7M shares 232.4M shares
Diluted Shares Outstanding 283.2M shares 280.1M shares 279.4M shares 237.7M shares 232.4M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $4.758 Billion

About Sotera Health Co

Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. The company is headquartered in Broadview Heights, Ohio and currently employs 3,000 full-time employees. The company went IPO on 2020-11-20. The Company’s segments include Sterigenics, Nordion, and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. The Nordion business is a provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and materials industries and for the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. The Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

Industry: Services-Misc Health & Allied Services, NEC Peers: 10X Genomics Inc Adaptive Biotechnologies Corp Neogenomics Inc Azenta Inc Cytek Biosciences Inc Syneos Health, Inc. Medpace Holdings Inc Pacific Biosciences of California Inc Thermo Fisher Scientific Inc